Cytokinetics (NASDAQ: CYTK) reported Q1 EPS of ($0.54), $0.07 worse than the analyst estimate of ($0.47). Revenue for the quarter came in at $8.5 million versus the consensus estimate of $6.86 million.

For earnings history and earnings-related data on Cytokinetics (CYTK) click here.